КАЧЕСТВО ЖИЗНИ БОЛЬНЫХ РАКОМ ШЕЙКИ МАТКИ В ЗАВИСИМОСТИ ОТ РЕЖИМА ПРОВЕДЕННОЙ ЛУЧЕВОЙ ТЕРАПИИ (original) (raw)

КАЧЕСТВО ЖИЗНИ БОЛЬНЫХ РАКОМ ШЕЙКИ МАТКИ В ЗАВИСИМОСТИ ОТ РЕЖИМА ПРОВЕДЕННОЙ ЛУЧЕВОЙ ТЕРАПИИ

Purpose: the aim of this study was to investigate quality of life of patients with cervical cancer depending on radiotherapy modality. Methods and materials: totally 246 patients were included. Distribution by FIGO stages was as follow: IIA – 44 (17,9%), IIВ – 115 (46,8%), IIIA – 13 (5,3%) и IIIВ – 74 (30%) patients. Depending on treatment modality all patients were divided into 3 groups: group I patients (n=72) received EBRT (46-50 Gy), HDR brachytherapy (2x9,0Gy) and concurrently cisplatin; group II patients (n=76) received the same treatment like group I but 4x7,5 Gy HDRBt; group III patients (n=98) received the same treatment like group II but without cisplatin. Results: Acute hematological toxicity was more severe in groups of concurrent chemoradiotherapy. Early local reactions were the same in all groups. Analysis of late toxicity did not reveal any differences between chemoradiotherapy and radiotherapy alone groups. Conclusion: concurrent chemoradiotherapy by use of two 9,0 Gy fractions and weekly infusions of cisplatin is quite effective, safe and cost saving treatment modality for locally advanced uterine cervical cancer with acceptable toxicity and patients’ QOL and could be carried out in daily clinical practice.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact